Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Asset disposition
Quarterly results
Acq. announced
Director departure
Appointed director
CC transcript
Notes have priced
Inv. presentation

LIGAND PHARMACEUTICALS INC (LGND) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 4 Espinoza Octavio (CFO) has filed a Form 4 on LIGAND PHARMACEUTICALS INC
Txns: Paid exercise price by delivering 346 shares @ $59.92, valued at $20.7k
09/27/2023 8-K Quarterly results
09/26/2023 4 Zimmermann Martine (Director) has filed a Form 4 on LIGAND PHARMACEUTICALS INC
Txns: Granted 2,285 shares @ $0
Granted 11,345 options to buy @ $59.08, valued at $670.3k
08/14/2023 4 Reardon Andrew (CHIEF LEGAL OFFICER &) has filed a Form 4 on LIGAND PHARMACEUTICALS INC
Txns: Paid exercise price by delivering 897 shares @ $68.73, valued at $61.7k
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Ligand Reports Second Quarter 2023 Financial Results Conference Call Begins at 4:30 p.m. Eastern Time Today"
07/10/2023 4 Korenberg Matthew E (PRESIDENT & CHIEF OPERATING) has filed a Form 4 on LIGAND PHARMACEUTICALS INC
Txns: Acquired 376 shares @ $56.78, valued at $21.3k
07/10/2023 4 Espinoza Octavio (CFO) has filed a Form 4 on LIGAND PHARMACEUTICALS INC
Txns: Acquired 375 shares @ $56.78, valued at $21.3k
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/18/2023 4 KOZARICH JOHN W (Director) has filed a Form 4 on LIGAND PHARMACEUTICALS INC
Txns: Sold 4,444 shares @ $77.2009, valued at $343.1k
05/16/2023 144 Form 144 - Report of proposed sale of securities:
05/10/2023 4 KOZARICH JOHN W (Director) has filed a Form 4 on LIGAND PHARMACEUTICALS INC
Txns: Sold 5,819 shares @ $76.511, valued at $445.2k
Sold 589 shares @ $77.0974, valued at $45.4k
Exercised 6,408 options to buy @ $18.82, valued at $120.6k
05/10/2023 144 Form 144 - Report of proposed sale of securities:
05/08/2023 144 Form 144 - Report of proposed sale of securities:
05/08/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
Docs: "Ligand Reports First Quarter 2023 Financial Results 2023 Financial Guidance Raised Conference Call Begins at 4:30 p.m. Eastern Time Today"
04/20/2023 ARS Form ARS - Annual Report to Security Holders:
04/20/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/20/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/28/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/13/2023 8-K Other Events  Interactive Data
02/28/2023 10-K Annual Report for the period ended December 31, 2022
02/27/2023 4 Espinoza Octavio (CFO) has filed a Form 4 on LIGAND PHARMACEUTICALS INC
Txns: Granted 6,046 shares @ $0
Granted 16,419 options to buy @ $75.09, valued at $1.2M
02/27/2023 4 Korenberg Matthew E (President & COO) has filed a Form 4 on LIGAND PHARMACEUTICALS INC
Txns: Granted 9,069 shares @ $0
Granted 24,628 options to buy @ $75.09, valued at $1.8M
02/27/2023 4 Reardon Andrew (See Remarks) has filed a Form 4 on LIGAND PHARMACEUTICALS INC
Txns: Granted 5,668 shares @ $0
Granted 15,393 options to buy @ $75.09, valued at $1.2M
02/27/2023 4 Davis Todd C (CEO) has filed a Form 4 on LIGAND PHARMACEUTICALS INC
Txns: Granted 17,005 shares @ $0
Granted 46,178 options to buy @ $75.09, valued at $3.5M
02/22/2023 8-K Quarterly results
Docs: "Ligand Reports Fourth Quarter and Full Year 2022 Financial Results 2023 Financial Guidance Raised Conference Call Begins at 4:30 p.m. Eastern Time Today"
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13D/A LIGAND PHARMACEUTICALS INC reports a 7.9% stake in Viking Therapeutics, Inc.
02/09/2023 SC 13G/A WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC reports a 0.8% stake in Ligand Pharmaceuticals Incorporated
02/06/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/04/2023 4 Espinoza Octavio (CFO) has filed a Form 4 on LIGAND PHARMACEUTICALS INC
Txns: Acquired 275 shares @ $56.78, valued at $15.6k
12/30/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/30/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy